Ibrutinib - CAS# 936563-96-1 Catalog No.:M10967-2 is a novel and selective

is a novel and selective voltage-gated sodium channel for pain treatment

and has been shown to improve mitochondrial function and to confer significant cellular protection in neurons under stress

4-b]indole-3-carboxamide

BMH-21 inhibits transcription of RNA polymerase I (Pol I) by binding to ribosomal (r) DNA that caused Pol I blockade and degradation of the large catalytic subunit of Pol I

Glut1 deficiency syndrome and erythrocyte glucose uptake assay

Ibrutinib - CAS# 936563-96-1 Catalog No.:M10967-2 is a novel and selectiveIbrutinib, also known as PCI 32765, is a potent and orally active BTK inhibitor. Ibrutinib binds to and inhibits BTK activity, preventing B cell activation and B cell mediated signaling and inhibiting the growth of malignant B cells that overexpress BTK. Ibrutinib was approved by the US FDA on November 13, 2013 for the treatment of mantle cell lymphoma. Product information CAS Number: 936563 96 1 Molecular Weight: 440. 50 Formula: C25H24N6O2 Synonym: